All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Miltenyi Biomedicine, Nurix Therapeutics, Roche, and Thermo Fisher Scientific and supported through independent educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
Primary endpoint met in TRANSCEND-CLL-004 trial of liso-cel in R/R CLL
Topline results obtained from TRANSCEND-CLL-004 (NCT03331198) show that the trial met its primary endpoint of complete response rate in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). The results indicate that lisocabtagene maraleucel (liso-cel) may be a safe and efficacious treatment option for this patient population.1
TRANSCEND-CLL-004 is a phase I/II, open-label, multicenter study to determine the efficacy and safety of liso-cel in adult patients with R/R CLL or small lymphocytic leukemia (SLL). The primary endpoint was complete response rate compared to historical control in patients with R/R CLL that was refractory to a Bruton’s tyrosine kinase (BTK) inhibitor and pretreated with a B-cell lymphoma 2 inhibitor. Additionally, no new safety signals were observed.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What is the primary reason you use bridging therapy in patients with DLBCL awaiting CAR T-cell therapy?
